P53 and EGFR expression in colorectal cancer: a reappraisal of 'old' tissue markers in patients with long follow-up.

摘要: BACKGROUND Extensive research into the biology of colorectal cancer has identified a plethora molecular markers reputed to provide prognostic information. During last two decades conflicting results have been drawn on role p53 tumour suppressor gene and first member type receptor tyrosine kinase family, EGFR, prognosis, Mutational status associated with both improved reduced survival. EGFR length survival, increasing Dukes' stage lymph node metastases in several reports, but as many studies reported no association unfavourable parameters. The aim this study was evaluate expression patients an at least 5-year follow-up. PATIENTS AND METHODS Paraffin-embedded material retrospectively collected from 164 adenocarcinoma (50 rectal) patients, who had operated between 1994 2003. median follow-up 5 years (range: 1-14). were evaluated by immunohistochemistry. RESULTS Positive immunostaining observed 63.4% 43.9% respectively. positivity rates significantly interrelated (p = 0.004). No significant correlation found examined clinicopathological parameters except for advanced T-stage, which demonstrated associations 0.004), 0.0001) p53/EGFR coexpression 0.001). In univariate survival analysis (log rank test), 0.0001), lymphovascular invasion 0.005) perineural infiltration 0.004) overall cancer-specific while trend existed 0.06) 0.07). On multivariate analysis, only increased risk death (Cox regression p 0.0001, b-coefficient (SE): 1.898 (0.383). CONCLUSION overexpressed patient population T stage. context new therapeutic strategies using EGFR-targeted therapies, although remains controversial factor, expression-stage may play crucial decision initiate adjuvant treatment.